Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
indiana blog main
8
×
indiana top stories
life sciences
national blog main
biotech
boston blog main
clinical trials
raleigh-durham blog main
raleigh-durham top stories
amgen
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
teva pharmaceutical
calcitonin gene-related peptide
cancer
chronic migraine
drugs
fremanezumab
merck
migraine
migraine research foundation
What
drug
8
×
new
8
×
approval
fda
migraine
won
class
approved
bio
companies
decades
developed
drugs
eli
lilly
medicines
oks
pain
roundup
second
starts
acute
addresses
advantages
amgen
announced
arguments
bar
big
biogen’s
biopharmaceutical
brings
cancer
candidates
causes
cholesterol
commercialized
competitors
condition
convo
Language
unset
Current search:
new
×
drug
×
" indiana blog main "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines